President-elect Donald Trump's triumph over Democratic presidential candidate Hillary Clinton last night should fare well for the European pharmaceutical industry, according to Business Insider.
Here are four key points:
1. Some major companies' stocks have soared following the news of a Republican win, with Roche and Novartis, both based in Switzerland, shares both jumping 4 percent.
2. British-based GlaxoSmithKline shares are trading 1.8 percent higher.
3. Business Insider reports this pricing surge following the election results is due to the fact that President-elect Donald Trump will likely not pass very controlling drug pricing legislation.
4. Chicago-based Deutsche Bank analysts had said, "European healthcare would likely outperform under a Trump win, given it has moved inversely to the probability of a Clinton victory over the past couple of months and has historically done well in periods of rising macro uncertainty and dollar strength."
More healthcare news:
What will happen to value-based care under the Donald Trump presidency?
10 key steps to immediately improve ASC finances
Donald Trump's alternative to ACA adds $41B+ to the deficit: 5 key notes